The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19

Overview

Journal Top Curr Chem (Cham)

Publisher Springer

Specialty Chemistry

Date 2021 Oct 8

PMID 34623536

Citations 20

Authors

Iqrar Ahmad

Rahul Pawara

Sanjay Surana

Harun Patel

Affiliations

Soon will be listed here.

Abstract

The highly infectious disease COVID-19 is induced by SARS-coronavirus 2 (SARS-CoV-2), which has spread rapidly around the globe and was announced as a pandemic by the World Health Organization (WHO) in March 2020. SARS-CoV-2 binds to the host cell's angiotensin converting enzyme 2 (ACE2) receptor through the viral surface spike glycoprotein (S-protein). ACE2 is expressed in the oral mucosa and can therefore constitute an essential route for entry of SARS-CoV-2 into hosts through the tongue and lung epithelial cells. At present, no effective treatments for SARS-CoV-2 are yet in place. Blocking entry of the virus by inhibiting ACE2 is more advantageous than inhibiting the subsequent stages of the SARS-CoV-2 life cycle. Based on current published evidence, we have summarized the different in silico based studies and repurposing of anti-viral drugs to target ACE2, SARS-CoV-2 S-Protein: ACE2 and SARS-CoV-2 S-RBD: ACE2. This review will be useful to researchers looking to effectively recognize and deal with SARS-CoV-2, and in the development of repurposed ACE2 inhibitors against COVID-19.

Citing Articles

Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds.

Lu J, Tang Y, Li H, Chen X, Qin P, Xu J Int J Mol Sci. 2025; 26(5).

PMID: 40076865 PMC: 11900932. DOI: 10.3390/ijms26052243.

Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses.

Ridgway H, Apostolopoulos V, Moore G, Kate Gadanec L, Zulli A, Swiderski J Viruses. 2024; 16(11).

PMID: 39599890 PMC: 11599072. DOI: 10.3390/v16111776.

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.

Bolinger A, Li J, Xie X, Li H, Zhou J Expert Opin Drug Discov. 2024; 19(9):1023-1041.

PMID: 39078037 PMC: 11390334. DOI: 10.1080/17460441.2024.2385598.

The Evaluation of Drugs as Potential Modulators of the Trafficking and Maturation of ACE2, the SARS-CoV-2 Receptor.

Alkhofash N, Ali B Biomolecules. 2024; 14(7).

PMID: 39062478 PMC: 11274373. DOI: 10.3390/biom14070764.

Anti-SARS-CoV-2 Viral Activity of Sweet Potato Trypsin Inhibitor via Downregulation of TMPRSS2 Activity and ACE2 Expression In Vitro and In Vivo.

Jiang W, Deng J, Yu C, Lin J, Huang G Int J Mol Sci. 2024; 25(11).

PMID: 38892254 PMC: 11172529. DOI: 10.3390/ijms25116067.

References

Liu C, Zhou Q, Li Y, Garner L, Watkins S, Carter L . Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020; 6(3):315-331. PMC: 10467574. DOI: 10.1021/acscentsci.0c00272. View

Singh Malik Y, Sircar S, Bhat S, Sharun K, Dhama K, Dadar M . Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020; 40(1):68-76. PMC: 7054940. DOI: 10.1080/01652176.2020.1727993. View

Wan Y, Shang J, Graham R, Baric R, Li F . Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7). PMC: 7081895. DOI: 10.1128/JVI.00127-20. View

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8):875-9. PMC: 7095783. DOI: 10.1038/nm1267. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X . High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1):8. PMC: 7039956. DOI: 10.1038/s41368-020-0074-x. View

Bosch B, van der Zee R, de Haan C, Rottier P . The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003; 77(16):8801-11. PMC: 167208. DOI: 10.1128/jvi.77.16.8801-8811.2003. View

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View

Reusken C, Haagmans B, Muller M, Gutierrez C, Godeke G, Meyer B . Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013; 13(10):859-66. PMC: 7106530. DOI: 10.1016/S1473-3099(13)70164-6. View

10.

Wang B, Kovalchuk A, Li D, Rodriguez-Juarez R, Ilnytskyy Y, Kovalchuk I . In search of preventive strategies: novel high-CBD extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY). 2020; 12(22):22425-22444. PMC: 7746344. DOI: 10.18632/aging.202225. View

11.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

12.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

13.

Sinha S, Shakya A, Prasad S, Singh S, Gurav N, Prasad R . An evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn. 2020; 39(9):3244-3255. PMC: 7232888. DOI: 10.1080/07391102.2020.1762741. View

14.

de Groot R, Baker S, Baric R, Brown C, Drosten C, Enjuanes L . Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790-2. PMC: 3700179. DOI: 10.1128/JVI.01244-13. View

15.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

16.

Luan J, Lu Y, Jin X, Zhang L . Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. Biochem Biophys Res Commun. 2020; 526(1):165-169. PMC: 7102515. DOI: 10.1016/j.bbrc.2020.03.047. View

17.

Han D, Penn-Nicholson A, Cho M . Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 2006; 350(1):15-25. PMC: 7111894. DOI: 10.1016/j.virol.2006.01.029. View

18.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

19.

Fraga-Silva R, Sorg B, Wankhede M, DeDeugd C, Jun J, Baker M . ACE2 activation promotes antithrombotic activity. Mol Med. 2010; 16(5-6):210-5. PMC: 2811560. DOI: 10.2119/molmed.2009.00160. View

20.

Tang B, Bragazzi N, Li Q, Tang S, Xiao Y, Wu J . An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020; 5:248-255. PMC: 7029158. DOI: 10.1016/j.idm.2020.02.001. View